<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>residual nausea &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/residual-nausea/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 24 Oct 2026 03:55:23 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>residual nausea &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Survey Finds Nausea Often Persists During Cancer Therapy Despite Widespread Antiemetic Use</title>
		<link>https://bioengineer.org/survey-finds-nausea-often-persists-during-cancer-therapy-despite-widespread-antiemetic-use/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sat, 24 Oct 2026 03:55:23 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[5-HT3 receptor antagonists]]></category>
		<category><![CDATA[anticancer therapy]]></category>
		<category><![CDATA[antiemetic guidelines]]></category>
		<category><![CDATA[chemotherapy-induced nausea and vomiting]]></category>
		<category><![CDATA[cross-sectional survey]]></category>
		<category><![CDATA[delayed nausea]]></category>
		<category><![CDATA[emetic risk]]></category>
		<category><![CDATA[guideline adherence]]></category>
		<category><![CDATA[multidrug prophylaxis]]></category>
		<category><![CDATA[NCCN Antiemesis]]></category>
		<category><![CDATA[residual nausea]]></category>
		<category><![CDATA[supportive care]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=451126</guid>

					<description><![CDATA[A cross-sectional survey of 624 physician-completed records found that nausea, especially delayed and residual nausea, remained frequent during anticancer therapy, while documented multidrug prophylaxis for high-emetic-risk regimens met guideline proxies in only a small fraction of cases.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">451126</post-id>	</item>
	</channel>
</rss>
